The importance of increased IGF1R expression in this context was confirmed in the same study by demonstrating that idelalisib-resistant CLL cells were sensitive to a specific IGF1R inhibitor. This evidence concerns the gene IGF1R and B-cell chronic lymphocytic leukemia.